Cao et al. [30] conducted a cohort study of 11 patients diagnosed with R/R lymphoma who were treated with anti-CD19 CAR-T therapy and nivolumab 3 mg/kg as a single dose on day +3 after CAR-T cell infusion. This evidence concerns the gene CD19 and lymphoma.